CD40 ligand deficiency is the IEI for which a gene edited T cell therapy is at the most advanced stage of development and it is expected that one or more of these approaches will enter clinical trials in humans in the near future. This evidence concerns the gene CD40LG and hyperinsulinemic hypoglycemia, familial, 4.